Chemotherapy Paclitaxel Adjuvant Therapy Improves Relapse-Free Survival the Addition of Paclitaxel to by Cmf Followed by Surgery (Arm C)

research highlights

chemotherapy paclitaxel adjuvant therapy improves relapse-free survival the addition of paclitaxel to by CmF followed by surgery (arm C). regimen resulted in a significant anthracycline-based adjuvant the addition of paclitaxel to adjuvant improvement in rFs and distant rFs. chemotherapy significantly improves doxorubicin significantly improved rFs and when paclitaxel was administered as relapse-free survival (rFs) in patients with distant rFs compared with the arm lacking neoadjuvant therapy, considerably more operable breast cancer, according to a new paclitaxel. the 7-year survival was similar patients received breast-sparing surgery. study. although taxanes are efficacious in between arms and remains <1% after 7 years the results of this trial also correlate with patients with advanced breast cancer, little of follow-up. there was no significant the findings of other trials demonstrating is known about the efficacy of different difference in rFs, however, when paclitaxel, that taxane-based adjuvant regimens are adjuvant and neo adjuvant regimens. doxorubicin and CmF were given before or superior to anthracycline-based regimens a multicenter, randomized, phase iii after surgery. the rate of breast-conserving in terms of improvements in recurrence study led by Gianni and coauthors in surgery was significantly greater for patients rate. this non-cross- resistant, sequential patients with advanced breast cancer, who received pre operative chemo therapy regimen represents another treatment assessed whether the addition of paclitaxel compared with postoperative treatment. option for patients with operable breast to an anthracycline-based regimen all three regimens were well tolerated with cancer, especially those who wish to administered preoperatively or no detrimental effect of adding paclitaxel avoid mastectomy. post operatively led to improved rFs. to anthracycline-based chemotherapy a total of 1,355 women were randomly or need for hemopoietic growth factor Lisa Hutchinson allocated to one of three arms: surgery support. long-term safety data indicate followed by doxorubicin followed by that cardiac function was well maintained Original article Gianni, L. et al. Phase III trial evaluating cyclophosphamide, methotrexate and in the majority of patients. the addition of the addition of paclitaxel to doxorubicin followed by 5-fluorouracil (CmF) chemotherapy paclitaxel did not seem to increase the risk cyclophosphamide, methotrexate, and fluorouracil, (arm a); surgery followed by paclitaxel of cardiac failure. as adjuvant or primary systemic therapy: European followed by CmF (arm B); or neo adjuvant incorporating paclitaxel into an anthra- Cooperative Trial in Operable Breast Cancer. J. Clin. Oncol. 27, 2474–2481 (2009). paclitaxel and doxorubicin followed cycline-based adjuvant chemotherapy

nature reviews | clinical oncology volume 6 | auGust 2009 | 437